CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 29 filers reported holding CUE BIOPHARMA INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $535,500 | +4.4% | 150,000 | -16.7% | 1.18% | -15.6% |
| Q4 2022 | $513,000 | +15.0% | 180,000 | -10.0% | 1.40% | +109.6% |
| Q3 2022 | $446,000 | +2.3% | 200,000 | +14.3% | 0.67% | +5.5% |
| Q2 2022 | $436,000 | -40.4% | 175,000 | +16.7% | 0.63% | -17.3% |
| Q1 2022 | $732,000 | -46.1% | 150,000 | +25.0% | 0.76% | -38.6% |
| Q4 2021 | $1,357,000 | -25.5% | 120,000 | -4.0% | 1.24% | -23.1% |
| Q3 2021 | $1,821,000 | +25.1% | 125,000 | 0.0% | 1.62% | +32.6% |
| Q2 2021 | $1,456,000 | -14.8% | 125,000 | -10.7% | 1.22% | -18.7% |
| Q1 2021 | $1,708,000 | -2.5% | 140,000 | 0.0% | 1.50% | -2.7% |
| Q4 2020 | $1,751,000 | +141.9% | 140,000 | +75.0% | 1.54% | +100.9% |
| Q3 2018 | $724,000 | +103.4% | 80,000 | +166.7% | 0.77% | +113.6% |
| Q2 2018 | $356,000 | -15.6% | 30,000 | 0.0% | 0.36% | -29.0% |
| Q1 2018 | $422,000 | – | 30,000 | – | 0.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 820,000 | $11,636,000 | 12.56% |
| Prosight Management, LP | 552,060 | $7,834,000 | 3.66% |
| Nantahala Capital Management | 2,503,840 | $35,529,000 | 1.33% |
| MANGROVE PARTNERS IM, LLC | 601,398 | $8,534,000 | 1.18% |
| Voss Capital, LLC | 88,670 | $749,000 | 1.00% |
| Slate Path Capital LP | 870,694 | $12,355,000 | 0.95% |
| Avoro Capital Advisors LLC | 1,870,000 | $26,535,000 | 0.90% |
| Bleichroeder LP | 165,000 | $2,341,000 | 0.61% |
| 683 Capital Management, LLC | 640,000 | $9,082,000 | 0.54% |
| PA Capital LLC | 40,706 | $578,000 | 0.51% |